Baolin Li

机构：Eli Lilly (United States), First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University · ORCID：0000-0002-8917-1687

发表论文 69 篇 · 总被引 2044 次 · h-index 20

代表论文

• Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells (2018 · Molecular Medicine Reports · 被引 60)
• Early functional rehabilitation compared with traditional immobilization for acute Achilles tendon ruptures (2021 · The Bone & Joint Journal · 被引 23)
• Phytochemical Analysis Using UPLC-MS/MS Combined with Network Pharmacology Methods to Explore the Biomarkers for the Quality Control of Lingguizhugan Decoction (2021 · Evidence-based Complementary and Alternative Medicine · 被引 21)
• ODMGIS: An Outlier Detection Method Based on Multigranularity Information Sets (2025 · IEEE Transactions on Fuzzy Systems · 被引 15)
• Quality evaluation of the classical prescription, Danggui Jianzhong decoction, using ultra‐high‐performance liquid chromatography fingerprint, chemical pattern recognition, and network pharmacology (2022 · Journal of Separation Science · 被引 14)
• Comprehensive characterization and identification of chemical constituents in Yangwei decoction using ultra high performance liquid chromatography coupled with electrospray ionization quadrupole time‐of‐flight tandem mass spectrometry (2021 · Journal of Separation Science · 被引 14)